Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $425,847.00 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Christopher Kenney sold 7,068 shares of the business’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $60.25, for a total transaction of $425,847.00. Following the transaction, the insider owned 2 shares of the company’s stock, valued at $120.50. This trade represents a 99.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xenon Pharmaceuticals Stock Performance

Xenon Pharmaceuticals stock opened at $60.40 on Friday. Xenon Pharmaceuticals Inc. has a fifty-two week low of $35.60 and a fifty-two week high of $72.66. The stock has a market cap of $5.84 billion, a P/E ratio of -12.74 and a beta of 0.61. The firm’s fifty day moving average price is $63.56 and its 200-day moving average price is $56.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same period in the prior year, the business posted ($1.07) EPS. Sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

XENE has been the topic of several research analyst reports. Needham & Company LLC decreased their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Wells Fargo & Company reiterated an “overweight” rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. HC Wainwright reissued a “buy” rating and issued a $74.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, August 10th. Royal Bank Of Canada lowered their price objective on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of “Buy” and an average target price of $77.13.

Institutional Trading of Xenon Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Corient Private Wealth LP lifted its holdings in shares of Xenon Pharmaceuticals by 1.5% in the 2nd quarter. Corient Private Wealth LP now owns 28,732 shares of the biopharmaceutical company’s stock worth $1,734,000 after acquiring an additional 430 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of Xenon Pharmaceuticals by 5,935.5% during the 2nd quarter. California State Teachers Retirement System now owns 5,597,786 shares of the biopharmaceutical company’s stock valued at $337,882,000 after purchasing an additional 5,505,039 shares during the last quarter. Headlands Technologies LLC grew its holdings in shares of Xenon Pharmaceuticals by 377.0% during the 2nd quarter. Headlands Technologies LLC now owns 29,194 shares of the biopharmaceutical company’s stock valued at $1,762,000 after purchasing an additional 23,074 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Xenon Pharmaceuticals in the 2nd quarter worth $206,000. Finally, Hsbc Holdings PLC raised its position in Xenon Pharmaceuticals by 24.6% in the 2nd quarter. Hsbc Holdings PLC now owns 151,474 shares of the biopharmaceutical company’s stock worth $9,143,000 after purchasing an additional 29,916 shares during the period. Institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.